Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drug
Another immune checkpoint inhibitor has demonstrated a life-extending benefit in non-small cell…
Browsing Tag
AntiPD1L1
Time’s Up for Anti-PD-1/L1 Plus Targeted Therapy in BRAF Melanoma
Adding an immune checkpoint inhibitor (ICI) to targeted therapy did not improve outcomes in…